Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

Ellen S. Vitetta, Joan E. Smallshaw, John Schindler

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.

Original languageEnglish (US)
Pages (from-to)1697-1699
Number of pages3
JournalClinical and Vaccine Immunology
Volume19
Issue number10
DOIs
StatePublished - Oct 2012

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine'. Together they form a unique fingerprint.

  • Cite this